The Life Sciences team advised Laronde on its $440 million Series B Financing to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories. The financing round included the company's founder, Flagship Pioneering, along with a wide group of public and private investors.

Laronde is pioneering a platform that offers a completely novel way of modulating human biology. Endless RNA™ (eRNA), invented at Flagship Labs, is a uniquely engineered RNA that can be programmed to express diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery.

Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $130 billion in aggregate value.

The Goodwin team was led by Stuart Cable, Danielle Lauzon, Tim Ayotte, Kathryn Weston, and Ryan Donahoe (Corporate); and included Paul Jin and Simone Waterbury (Antitrust); Richard Matheny and Justin Pierce (Global Trade); Dan Karelitz (Tax); and Mark Burnett (Opinions).

For more details, read the press release and articles in Endpoints, Fierce Biotech, and BioPharma Dive.